{"name":"William Sikov MD","slug":"william-sikov-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cohort 1 neo-adjuvant","genericName":"Cohort 1 neo-adjuvant","slug":"cohort-1-neo-adjuvant","indication":"Unresectable or metastatic melanoma","status":"phase_2"}]}],"pipeline":[{"name":"Cohort 1 neo-adjuvant","genericName":"Cohort 1 neo-adjuvant","slug":"cohort-1-neo-adjuvant","phase":"phase_2","mechanism":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","indications":["Unresectable or metastatic melanoma","Locally advanced or metastatic non-small cell lung cancer","Locally advanced or metastatic renal cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}